Affordable Access

deepdyve-link
Publisher Website

Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.

Authors
  • Wormser, Gary P
  • Prasad, Aakanksha
  • Neuhaus, Ellen
  • Joshi, Samit
  • Nowakowski, John
  • Nelson, John
  • Mittleman, Abraham
  • Aguero-Rosenfeld, Maria
  • Topal, Jeffrey
  • Krause, Peter J
Type
Published Article
Journal
Clinical Infectious Diseases
Publisher
Oxford University Press
Publication Date
Feb 01, 2010
Volume
50
Issue
3
Pages
381–386
Identifiers
DOI: 10.1086/649859
PMID: 20047477
Source
Medline
License
Unknown

Abstract

B. microti may become resistant to azithromycin-atovaquone during the treatment of babesiosis with this combined drug regimen in highly immunocompromised patients. Although research is needed to determine the optimal therapy for highly immunocompromised patients with babesiosis, reducing the level of immunosuppression when possible would appear to be a desirable strategy.

Report this publication

Statistics

Seen <100 times